Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
PipCast®
PTE
Trade Marks
Webinars

‘Repair’ defence to patent infringement and the perils of hindsight bias

MMD Design and Consultancy Limited v Camco Engineering Pty Ltd [2023] FCA 827

Date:

Court:

Judges:

21 July 2023

Federal Court of Australia

Rofe J

Highlight

The repair defence entitles the purchaser of a patented product to repair it or retain a third party to do so.  But this right does not extend to remaking the entire product under the guise of repair so as to avoid patent infringement.

Background

MMD Design and Consultancy Limited owns a patent entitled “A tooth construction for a mineral breaker”, AU2004289510 (the Patent).  A mineral breaker/sizer is used in mining to break mineral ore into smaller sizes.  The machine has teeth with sacrificial covers welded to each other and/or the tooth-shaped support body underneath.  The covers are formed of degradable parts which need replacing after prolonged use.  Camco Engineering Pty Ltd provided an after-market repair service by which it dismantled the tooth constructions down their base components, replaced the worn out covers and rebuilt the tooth constructions, initially for MMD under contract, a service it continued to provide directly to MMD customers in competition with MMD, after its contract with MMD terminated in 2015.

MMD alleged Camco infringed the Patent by supplying five unauthorised welded tooth constructions to mines operated by BHP, Fortescue Metals and South32.  MMD also asserted that Camco engaged in misleading and deceptive conduct in breach of the Australian Consumer Law (ACL) by failing to warn its customers of the existence of the Patent and that Camco’s acts infringed certain claims of the Patent.

Camco asserted it did not infringe, and (alternatively) it characterises its services as ‘refurbishment’ or repair which Camco had undertaken as agent for the miners, which is permissible under the exhaustion doctrine.  It denied the ACL allegations, and cross claimed for revocation on the grounds of lack of manner of manufacture, novelty, inventive step, and fair basis.

Neither party was successful, with the result that the patent was held valid but not infringed by Camco because of a successful design-around strategy.  Rofe J found that, had it been infringed, the ‘repair’ defence would not apply as Camco’s ‘repairs’ would amount to an impermissible remaking of the invention rather than permissible repair.

MMD appealed to the Full Federal Court on 19 September 2023.

Key Issues

The doctrine of exhaustion and the repair defence

The critical question to be determined is whether Camco engaged in ‘permissible repair’ or ‘impermissible manufacture’, following the principles set out by the High Court in 2020 in Calidad v Seiko 1.  The Court in Calidad confirmed that a patentee’s rights to exploit a patented product (that is, to “make, hire, sell or otherwise dispose of or use” the product), are exhausted on sale of the product.  The Court held that the ‘exhaustion doctrine’ prevails over the alternative ‘implied licence’ doctrine but neither doctrine entitles the purchaser to recreate or manufacture new products that fall within the scope of the claims.

In Calidad, the defendants modified Calidad’s patented single-use printer cartridges to make them refillable.  The High Court held this was a permissible repair because it did not involve “unmaking” and “remaking” the product nor replicating the patented elements.  The High Court contrasted this to the circumstances addressed in a UK decision, United Wire2 in which the defendants stripped down patented shifting screens to their frames (likened to a “skeleton or chassis”) and secured new mesh screens.  This was deemed equivalent to purchasing frames on the open market and then using them to create a new assembly, leading to a finding of patent infringement.

Validity and hindsight bias in inventive step evidence

A secondary aspect of this case was the court’s approach to independent expert evidence led by Camco.  The expert was shown MMD’s patent before being shown any prior art, none of which were considered common general knowledge (CGK).  The expert was unaware of problems related to bolted tooth constructions when he read the prior art.

Outcome

Justice Rofe rejected MMD’s submission  on construction, and consequently rejected the infringement and ACL claims.  For the latter, it was pertinent that Camco had obtained legal advice, and held an honest belief that the repaired products did not infringe.

Despite the finding of non-infringement, Justice Rofe considered Camco’s ‘repair defence’.  She observed that when Camco dismantled the construction down to the support body by removing the covers, it effectively unmade the tooth construction, and ‘remade’ a new one when putting it all back together.  Her Honour likened the remaining support body (which was not technically repaired) to the “skeleton or chassis” in United Wire, and considered the Camco services an impermissible repair not covered by the doctrine of exhaustion.  Consequently, had there been infringement, the repair defence would not have exempted Camco.

Rofe J noted that the patent’s claims specifically pertained to a tooth construction for a mineral breaker and not to a complete mineral breaker that happened to include tooth constructions.  Had MMD claimed the entire mineral sizer together with the tooth construction, Camco’s repair defence may have succeeded.

Justice Rofe was critical of the preparation of Camco’s expert evidence which was “impermissibly assisted by hindsight.”   Unconventionally, materials scientist Dr Paul Huggett, Camco’s sole expert witness, was provided the patent before he was provided with 5 pieces of prior art.  He was not asked to carry out literature searches or opine on what he would have done in light of common general knowledge (CGK) alone or in combination with the art before he studied the patent.  In providing his evidence, Dr Huggett conceded that ‘he started with the solution presented in the Patent’.

Camco also failed on the grounds of novelty and fair basis.

MMD filed a notice of appeal on 19 September 2023.

Implications

Subject to the appeal, this decision highlights the importance of distinguishing between permissible repair and impermissible manufacture in patent law. Modifications must not replicate the combination of claimed features in a patent claim if they are to qualify as permissible repair under the exhaustion doctrine.

Additionally, the case underscores the perils of expert evidence tainted by hindsight bias in expert evidence and reinforces that practitioners must remain vigilant to avoid such bias.  Camco has provided an example of what not to do in the preparation of expert evidence in Australia.

___
1 [2020] HCA 41
2 [2001] RPC 24

About Pearce IP

Pearce IP is a boutique firm offering intellectual property specialist lawyers, patent attorneys and trade mark attorneys to the life sciences industries (in particular, pharmaceutical, biopharmaceutical, biotech, ag-tech and food tech).  Pearce IP is the 2021 ‘Intellectual Property Team of the Year’ (Lawyers Weekly Australian Law Awards) and was shortlisted for the same award in 2022.  Pearce IP is ranked in IAM Patent 1000 and Managing IP (MIP) IP Stars, in Australasian Lawyer 5 Star Awards as a ‘5 Star’ firm, and the Legal 500 APAC Guide for Intellectual Property.

Our leaders have been recognised in virtually every notable IP listing for their legal, patent and trade mark excellence including: IAM Patent 1000, IAM Strategy 300, MIP IP Stars, Doyles Guide, WIPR Leaders, 5 Star IP Lawyers, Best Lawyers, and Australasian Lawyer 5 Star Awards, and have been honoured with many awards including Australian Law Awards – IP Partner of the Year, Women in Law Awards – Partner of the Year, Women in Business Law Awards – Patent Lawyer of the Year (Asia Pacific), Most Influential Lawyers (Changemaker), among other awards.

Naomi Pearce

Naomi Pearce

CEO, Executive Lawyer (AU, NZ), Patent & Trade Mark Attorney (AU, NZ)

Naomi is the founder of Pearce IP, and is one of Australia’s leading IP practitioners.   Naomi is a market leading, strategic, commercially astute, patent lawyer, patent attorney and trade mark attorney, with over 25 years’ experience, and a background in molecular biology/biochemistry.  Ranked in virtually every notable legal directory, highly regarded by peers and clients, with a background in molecular biology, Naomi is renown for her successful and elegant IP/legal strategies.

Among other awards, Naomi is ranked in Chambers, IAM Patent 1000, IAM Strategy 300, is a MIP “Patent Star”, and is recognised as a WIPR Leader for patents and trade marks. Naomi is the 2023 Lawyers Weekly “IP Partner of the Year”, the 2022 Lexology client choice award recipient for Life Sciences, the 2022 Asia Pacific Women in Business Law “Patent Lawyer of the Year” and the 2021 Lawyers Weekly Women in Law SME “Partner of the Year”.  Naomi is the founder of Pearce IP, which commenced in 2017 and won 2021 “IP Team of the Year” at the Australian Law Awards.

Kate Legge

Kate Legge

Special Counsel, Lawyer

Kate is an experienced IP and patent lawyer, providing IP leadership for pharmaceutical product development and commercialisation in global markets – from initial scoping through to post-launch.

She has developed and implemented global IP strategies over more than 15 years at multi-national pharmaceutical companies. She is an Australian qualified and registered legal practitioner, and has a Master’s degree in IP Law and a BSc in biochemistry.

Donna Meredith

Donna Meredith

Associate, Patent & Trade Mark Attorney

Donna is a Patent and Trade Mark Attorney with more than 8 years’ post-qualification experience, and a background in biotechnology and biology.

Donna supports Australian and international clients in a range of life sciences fields including nanoparticles, pharmaceuticals, biopharmaceuticals, biotechnology, DNA sequencing, cell and gene therapy, CRISPR technologies, protein chemistry, formulation chemistry, chemical compounds, biofuels, plant varieties, ag-tech, food-tech and medical devices.

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.

Our Latest News